WFDC2 and breast cancer: BreastMark analysis revealed that higher HE4 expression was significantly associated with improved survival in both the overall breast cancer cohort (HR = 0.838, 95% CI: 0.75–0.94, p = 0.003, n = 2652) and the lymph node-negative subgroup (HR = 0.791, 95% CI: 0.64–0.97, p = 0.029, n = 1183) (Figure 4).